Alnylam Pharmaceuticals Inc

ALNY:NASDAQ
RT Quote | NASDAQ | USD
Last | 01/25/21 EST
175.69quote price arrow up+3.31 (+1.92%)
Volume
1,065,668
52 week range
84.97 - 176.78

...

Loading . . .

KEY STATS

  • Open170.43
  • Day High176.78
  • Day Low168.15
  • Prev Close175.69
  • 52 Week High176.78
  • 52 Week High Date01/25/21
  • 52 Week Low84.97
  • 52 Week Low Date03/13/20
  • Market Cap20,411.66M
  • Shares Out116.18M
  • 10 Day Average Volume1.14M
  • Dividend-
  • Dividend Yield-
  • Beta1.38
  • 1 Year % Change46.41

RATIOS/PROFITABILITY

  • EPS (TTM)-7.83
  • P/E (TTM)-22.44
  • Fwd P/E (NTM)-26.70
  • EBITDA (MRQ)-902.46M
  • ROE (MRQ)-63.14%
  • Revenue (MRQ)400.97M
  • Gross Margin (MRQ)83.24%
  • Net Margin (MRQ)-222.19%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date02/04/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Alnylam Pharmaceuticals Inc News

There is no recent news for this security.

Latest ALNY News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple...
Michael Bonney
Chairman
John Maraganore Ph.D.
Chief Executive Officer
Yvonne Greenstreet
President
Jeffrey Poulton
Chief Financial Officer
Laurie Keating
Executive Vice President
Address
675 W Kendall St
Cambridge, MA
02142-1168
United States